ResMed shares can overcome obesity-drug craze, analysts say
Shares of ResMed Inc. (RMD), which have been pounded in recent weeks by concerns that the obesity-drug craze could hurt demand for the company's sleep therapy devices, are poised for a turnaround, according to Needham analysts. Although GLP-1 drugs, such as Novo Nordisk's (NOVO-B.KO) Ozempic and Wegovy, may cause some patients to stop using CPAP machines as their sleep apnea becomes less severe, "these impacts are likely to be small," the analysts wrote in a note Wednesday, saying that ResMed can sustain 5% to 7% revenue growth and double-digit per-share earnings growth for the next few years. The analysts raised their rating on ResMed shares to buy, from hold, and set a $180 price target for the stock. ResMed shares gained 1% premarket on Wednesday and have dropped 26% in the year to date, while the S&P 500 has gained 17%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-06-23 0857ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations